Visiomed begins clinical evaluation trials of microEYE™
Australia, Monday June 27 2005: Biomedical devices developer, Visiomed Group Ltd (ASX:VSG) and ophthalmic surgical laser
group, CustomVis (AIM:CUS), announced today that their ophthalmic imaging system, microEYE™, has begun a clinical
evaluation trial.
The microEYE™ is a hand-held camera system capable of imaging different regions of the eye using one device, instead of
using a number of devices. The device also provides digital capture-storage-retrieval images to enable immediate
diagnosis and continued monitoring.
The microEYE™ is targeted for use in the diagnosis and monitoring of eye pathologies associated with the posterior
segment, such as diabetic retinopathy, glaucoma and macular degeneration as well as pathologies associated with the
anterior segment such as trachoma and cataracts.
The clinical evaluation of the microEYE™ will be undertaken by between 20 to 25 optometrists and ophthalmologists and
will take place over the next months.
“This is an exciting step towards the commercialisation of the microEYE™. We have selectively chosen optometrists and
ophthalmologists that will hopefully become strong advocates of the technology,” said Mr William Dolphin, CEO of
Visiomed.
A prototype microEYE™ System was recently displayed at the joint meeting of the American Society of Cataract and
Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS/ASOA) in Washington, DC. Some of the
competitive advantages of the microEYE™ will include pricing, system portability, multi-functionality for disease
screening, ease-of-use, archiving and telemedicine facilities.
In excess of 160 million people suffer from disabling visual problems worldwide, according to the World Heath
Organization figures, a figure that is expected to double by the year 2030. Early diagnosis and continued monitoring of
eye diseases such as cataract, glaucoma, macular degeneration and diabetic retinopathy could prevent the onset of
blindness in most cases.
About Visiomed Group Ltd
Visiomed (www.visiomed.com.au) develops and commercialises innovative medical devices. Apart from the Funhaler®,
Visiomed also has the exclusive world wide licences for computer-based smart systems for the imaging and diagnosis of
diseases other than dermatological conditions. The company is utilising its intellectual property to develop the
microEYE™imaging system as an aid in the screening and diagnosis of eye diseases such as cataract, glaucoma, trachoma,
macular degeneration and diabetic retinopathy.
About CustomVis
CustomVis develops, manufactures and commercialises solid state laser optical equipment for use within the laser vision
correction industry. The production Quality System is certified to ISO 13485 for Medical Devices. The company has
proprietary intellectual property and patents covering its laser optical systems and eye tracking technologies.
CustomVis is listed on the London Alternative Investment Market (London AIM code CUS.)
ENDS